



Press Release

## **Cipla announces Q4 & FY 17 results**

### **Continued strong performance across key markets**

---

**Mumbai, India, May 25, 2017:** Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its audited financial results for the full year and quarter ended March 31, 2017. The Company reported quarterly revenues of Rs 3,582 crores, growing 8% y-o-y. The R&D investments in the quarter have ramped up to 8.6% of revenues, a 160bps increase as compared to YTD Dec'16. For the full year, consolidated revenue stood at Rs 14,630 crores, with EBITDA margin at ~17% of sales accompanied by the continued strong performance in key markets.

**Commenting on the results, Umang Vohra, MD and Global CEO, Cipla Ltd** said, “We have achieved significant progress on our identified key priorities and have strengthened our core business through consolidation, complexity reduction and deepening our presence in priority markets. This year, we have had good traction on our pipeline with 32 US ANDA filings and a proof of concept of our capabilities for the respiratory franchise for the advanced markets with approval of Sereflo™ in UK and Albuterol MDI filing in the US. While the quarterly results are off the mark due to a tough operating environment and certain one-offs, we delivered on our goal of improving base EBITDA percentage year-on-year by more than 200 bps.”

#### **Key Financial Highlights**

---

##### **Q4 FY17:**

- Income from operations at Rs 3,582 cr
- EBITDA at Rs 506 cr
- Profit/(Loss) after tax is Rs (62) cr
- R&D investment at Rs 307 cr
- Cash generated from operations Rs 389 cr

#### **Performance Highlights for Q4 & FY17**

---

- Successfully integrated all the major operational aspects of InvaGen and Exelan with Cipla Global operations. As per IMS MAT Mar'17, Cipla has attained 9<sup>th</sup> rank in TRx amongst all generic companies in US reflecting a successful integration and our strong execution capabilities in the market
- Launched 2 in-licensed brands in India from Novartis- Azmarda and Bolstran

- Divestment of South Africa based Animal Health business to Ascendis Pharma (subject to customary closing conditions).
- Strengthened focus on CNS, with signing of a worldwide licensing agreement (except for East Asia) with MEDRx to develop and commercialize MRX-4TZZT, a Tizanidine patch for the management of Spasticity.
- The results for the quarter include one-off charges related to impairment of a part of intangibles from our US acquisition and a provision for loss on certain assets of our subsidiary Cipla BioTec Pvt. Ltd.
- India business recorded healthy growth of ~10% for the full year as against IPM growth of 9%, with most therapies retaining leadership position
- Cipla is now the 3<sup>rd</sup> largest pharmaceutical company in South Africa. South Africa business continued strong growth across both private market and tender business, with FY17 sales growing by ~17% compared to last year in local currency terms.
- Successfully turned around the European business model bringing it back on the profitability curve
- The financial year saw filling of 32 ANDAs, much ahead of the guidance range of 20-25 ANDAs. On the Respiratory front, we successfully launched FPSM in Europe and filed our first MDI - Albuterol in the US

#### **Overall P&L (in INR Cr)**

<b>CONSOLIDATED ( IND AS)*</b>	<b>Q4 FY17</b>	<b>Q4 FY16</b>	<b>Growth%</b>	<b>FY17</b>	<b>FY16</b>	<b>Growth%</b>
<b>Total Income from Operations</b>	<b>3582</b>	<b>3315</b>	<i>8.1%</i>	<b>14630</b>	<b>13790</b>	<i>6.1%</i>
<b>EBITDA</b>	<b>506</b>	<b>176</b>	<i>187.4%</i>	<b>2476</b>	<b>2480</b>	<i>-0.2%</i>
% of Income from Operations	<i>14%</i>	<i>5%</i>		<i>17%</i>	<i>18%</i>	
<b>PBT</b>	<b>-137</b>	<b>-82</b>	<i>na</i>	<b>1222</b>	<b>1727</b>	<i>-29.2%</i>
% of Income from Operations	<i>-4%</i>	<i>-2%</i>		<i>8%</i>	<i>13%</i>	
<b>PAT</b>	<b>-62</b>	<b>-93</b>	<i>na</i>	<b>1006</b>	<b>1360</b>	<i>-26.0%</i>
% of Income from Operations	<i>-2%</i>	<i>-3%</i>		<i>7%</i>	<i>10%</i>	

*\*Y-o-Y numbers are not comparable as FY16 includes Esomeprazole profit share while FY17 includes the contribution from US acquisitions of InvaGen and Exelan.*

### Key Balance Sheet Items (in INR Cr)

Balance Sheet Items	Mar'17	Mar'16
Equity	12,525	11,516
Total Debt	4,113	5,192
Inventory	3,485	3,808
Cash and Cash Equivalents*	1,462	1,454
Trade and Other Receivables	2,890	2,493
Net Tangible Assets	5,730	5,347
Goodwill & Intangibles	5,427	6,083

\* includes current investments

### Revenue break-up (in INR Cr)#

Business	Q4 FY17	Q4 FY16	Growth	FY17	FY16	Growth
India (Rx + Gx)	1,197	1248	-4%	5,530	5,022	10%
South Africa	468	313	50%	1827	1569	16%
North America	646	486	33%	2624	2105	25%
Europe	180	167	8%	543	606	-10%
Emerging Markets	813	895	-9%	3161	3409	-7%
API	162	179	-10%	527	738	-29%
Rest*	116	28	321%	418	340	23%
<b>Total</b>	<b>3,582</b>	<b>3,315</b>	<b>8%</b>	<b>14,630</b>	<b>13,790</b>	<b>6%</b>

\*Includes CNV business, Vet and others

#Y-o-Y numbers are not comparable as FY16 includes Esomeprazole profit share while FY17 includes the contribution from US acquisitions of InvaGen and Exelan.

### About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

#### **Contacts:**

##### **Investor Relations**

Alpesh Dalal

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)

##### **Corporate Communications**

Pallavi Golar

E-Mail: [pallavi.golar@cipla.com](mailto:pallavi.golar@cipla.com)